Rallybio Corp Form 8-K Summary
Business Context and Reporting Period
Rallybio Corporation, an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on March 13, 2025. The filing addresses an amendment to an existing securities sales agreement.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed relates to the cap on a potential equity offering:
- Amended Offering Cap: Reduced from $100,000,000 to $9,550,000.
- Shares Sold to Date: $0 under the Sales Agreement as of the report date.
- Commission Rate: Up to 3.0% of gross proceeds.
Material Changes
On March 13, 2025, the Company entered into Amendment No. 1 to its Sales Agreement with TD Securities (USA) LLC ("TD Cowen"). The primary material change is the significant reduction in the aggregate offering price of common stock available for sale under the agreement from $100 million to $9.55 million. This reduction aligns with the Company's public float limitations under Instruction I.B.6 of Form S-3, which restricts sales to no more than one-third of the public float when that float is below $75 million.
Outlook, Risks, and Management Commentary
The Company retains the right to suspend offers or terminate the Sales Agreement at any time and has no obligation to sell shares. Sales, if any, will be conducted at market prices via "at the market" offerings. The filing notes that no securities have been offered pursuant to the public float restriction in the prior twelve-month period. No specific risks or contingencies beyond standard securities law compliance were detailed in this specific report.
Key Facts for Investor Verification
- Verify the Company's current public float to understand the $9.55 million sales cap constraint.
- Confirm the status of the effective registration statement (Form S-3, File No. 333-266668).
- Monitor future 8-K filings for any actual sales of shares under the amended agreement.
- Review the full text of Amendment No. 1 (Exhibit 1.1) for specific terms not summarized here.